GlassScriptPhysician profile
Philip M Lepkowski
NPI 1073513198
$26,152.15
in general payments reported to CMS, 2019-2025
53 companies · $2,509 in 2025
The $2,509 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,673 · 2020: $4,121 · 2021: $4,549 · 2022: $2,773 · 2023: $3,600 · 2024: $2,927 · 2025: $2,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,035.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,674.85 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $3,323.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $3,201.76 | 2019-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $1,976.90 | 2021-2025 | |
| Lilly USA, LLC | $1,462.17 | 2019-2025 | Jardiance, Emgality, Zepbound |
| Corcept Therapeutics | $1,449.11 | 2019-2025 | Korlym |
| Abbvie INC. | $1,320.78 | 2019-2025 | |
| Pfizer INC. | $1,143.42 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,091.92 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $782.02 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $705.98 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $667.63 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $596.00 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $371.71 | 2019-2020 | |
| Allergan, INC. | $361.71 | 2019-2020 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Lepkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.